Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Standard pharmacological treatment

Preclinical

UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

2

Indications

2

Total Trials

2

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

OcclusionNot yet recruiting

Posterior CirculationNot yet recruiting

OcclusionPreclinical

Not yet recruiting

Posterior CirculationPreclinical

Not yet recruiting

Timeline

Expected Milestones

Q3 2030

PreclinicalNot yet recruiting

Posterior Circulation

NCT07699029

PreclinicalNot yet recruiting

Occlusion

NCT07699003

Clinical

Trials by Indication[1]

Posterior Circulation1 trial

Endovascular Treatment for Posterior Circulation Ischemic Stroke Post 1 Day （24 Hours） A Randomized Controlled Clinical Trial On Efficacy

Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Preclinical·NCT07699029·244 enrolled

Occlusion1 trial

Endovascular Treatment of Chronic Intracranial Artery Occlusion: A Multicenter Randomized Controlled Trial

Not yet recruiting·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Preclinical·NCT07699003·382 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Standard pharmacological treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Standard pharmacological treatment. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Union Hospital, Tongji Medical College, Huazhong University of Science and Technology company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology

Related News